Group 1 - Company Yiduoli reported Q3 performance with revenue of approximately 613 million yuan, an increase of 0.77% year-on-year [1] - Net profit attributable to shareholders was approximately 18.2 million yuan, a decrease of 57.47% year-on-year [1] - Basic earnings per share were 0.0371 yuan, down 57.5% compared to the previous year [1] Group 2 - As of the report, the market capitalization of Yiduoli is 3.4 billion yuan [2]

Group 1 - Company Yiduoli (SZ 300381) announced on October 28 that its 15th meeting of the 8th board of directors was held via communication, where the proposal for the "2025 Q3 Report" was reviewed [1] - For the year 2024, Yiduoli's revenue composition is as follows: 83.57% from the biomanufacturing industry, 15.71% from the bio-agriculture and animal husbandry industry, and 0.72% from other industries [1] - As of the report date, Yiduoli's market capitalization is 3.4 billion yuan [1] Group 2 - The A-share market has surpassed 4000 points, marking a significant resurgence after a decade of stagnation, with technology leading the market's transformation into a new "slow bull" pattern [1]

股票代码：300381 股票简称：溢多利 公告编号：2025-051 广东溢多利生物科技股份有限公司 关于为全资子公司向银行申请授信额度提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 广东溢多利生物科技股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日召开的第八届董事会第十五次会议审议通过了《关于为全资子公司向银 行申请授信额度提供担保的议案》，公司全资子公司珠海瑞康生物科技有限公 司（以下简称"珠海瑞康"）因经营发展需要，拟向珠海华润银行股份有限公 司珠海分行申请人民币 1000 万元授信额度，期限三年，由公司为该笔授信额 度提供连带责任保证担保。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司 自律监管指引第 2 号——创业板上市公司规范运作》和《公司章程》的相关规 定，本次为全资子公司担保事项无需提交股东会审议。 二、担保额度预计情况 单位：万元 | 担保方 | 被担保方 | 担保方持股 | 被担保方最 近一期资产 | 截至目 前担保 | 本次新增 | 新增担保额 度占公司最 | 是否 ...

第八届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 股票代码：300381 股票简称：溢多利 公告编号：2025-049 广东溢多利生物科技股份有限公司 一、董事会会议召开情况 广东溢多利生物科技股份有限公司（以下简称"公司"）第八届董事会第 十五次会议于 2025 年 10 月 28 日在公司会议中心以通讯方式召开。会议通知 于 2025 年 10 月 17 日以信息、邮件等方式发送至公司全体董事。会议应出席 董事 7 名，实际出席会议董事 7 名。会议由董事长陈少美先生主持。本次会议 符合《公司法》和《公司章程》的有关规定，会议合法有效。 二、董事会会议审议情况 本次会议以投票表决方式审议通过了如下议案： 1、审议通过《关于公司<2025 年第三季度报告>的议案》。 经审议，董事会认为：公司《2025 年第三季度报告》符合法律、行政法 规、中国证监会和深圳证券交易所的规定，报告内容真实、准确、完整地反映 了公司 2025 年第三季度的经营情况，不存在任何虚假记载、误导性陈述或重 大遗漏。 具体内容详见公司同日在巨潮资讯网(ww ...

Revenue and Profit - The company's revenue for Q3 2025 was ¥198,105,771.47, representing a decrease of 6.21% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥4,207,421.47, a significant increase of 314.42% year-on-year, while the year-to-date net profit decreased by 57.47% to ¥18,204,377.42[5]. - The basic and diluted earnings per share for the quarter were both ¥0.0086, reflecting a 309.52% increase compared to the same period last year[5]. - Net profit for the current period was ¥19,488,498.12, down from ¥43,840,738.67, indicating a decrease of approximately 55.6%[21]. - Earnings per share (EPS) decreased to ¥0.0371 from ¥0.0873, a decline of about 57.5%[22]. Assets and Liabilities - Total assets at the end of Q3 2025 were ¥2,894,808,436.34, down 1.82% from the end of the previous year[5]. - Total assets amounted to ¥2,894,808,436.34, slightly down from ¥2,948,587,167.07, a decrease of approximately 1.8%[19]. - Total liabilities decreased to ¥258,966,454.95 from ¥294,388,193.40, a reduction of about 12.0%[19]. - The company's goodwill remained stable at ¥36,673,724.02, unchanged from the previous period[18]. - The total equity attributable to shareholders decreased to ¥2,588,840,856.67 from ¥2,611,511,969.65, a decrease of about 0.9%[19]. Cash Flow - The company reported a 40.51% decrease in cash flow from operating activities year-to-date, totaling ¥56,054,193.54[5]. - The net cash flow from operating activities decreased by 40.51% to ¥56,054,193.54, primarily due to a reduction in government subsidies received and an increase in cash paid for goods and services[12]. - The net cash flow from investing activities improved by 65.26% to -¥85,945,758.88, attributed to a decrease in payments for fixed assets, intangible assets, and other long-term assets[12]. - The net cash flow from financing activities dropped by 91.97% to ¥14,250,625.78, mainly due to the absence of large time deposits maturing compared to the previous year[12]. - The net increase in cash and cash equivalents was -¥13,804,376.00, a decline of 157.54% compared to the previous year, driven by reduced government subsidies and increased cash payments for goods and services[12]. Investments and Projects - The company is actively expanding its projects, including the construction of the Yidoli Science and Technology Park and other innovation projects in Inner Mongolia and Hunan[9]. - The construction in progress increased significantly from ¥294,120,540.51 to ¥402,740,681.97, suggesting ongoing investments in new projects[17]. Other Financial Metrics - The company experienced a 35.08% decrease in trading financial assets, amounting to ¥215,610,965.17, primarily due to reduced financial investments during the reporting period[9]. - Other receivables increased by 126.67% to ¥8,396,053.10, attributed to an increase in standby funds[9]. - The company reported a 93.06% decrease in non-operating income, totaling ¥688,529.77, mainly due to the previous year's acquisition-related gains[11]. - The company’s tax expenses decreased by 78.24% to ¥1,244,256.79, reflecting a reduction in total profit[11]. - Research and development expenses were ¥70,422,506.76, a decrease from ¥73,735,035.11, reflecting a reduction of about 4.2%[20]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,055, with no preferred shareholders having restored voting rights[14]. - Zhuhai Jindadi Investment Co., Ltd. holds 29.01% of shares, amounting to 142,458,378 shares, with 37,500,000 shares pledged[15].

Core Insights - The company Yiduoli stated that as of October 20, 2025, the number of shareholders is expected to reach 20,223 [2] Company Information - Yiduoli responded to investor inquiries on an interactive platform regarding shareholder numbers [2] - The projected number of shareholders indicates potential growth and interest in the company [2]

Core Viewpoint - Yidoli's stock price has shown a slight increase recently, but the overall performance this year has been negative, indicating potential challenges in the market [1][2]. Company Overview - Yidoli Biotechnology Co., Ltd. is located in Zhuhai, Guangdong Province, established on September 3, 1991, and listed on January 28, 2014. The company specializes in the research, production, sales, and service of biological enzyme preparations, steroid hormone raw materials, plant extracts, and animal nutrition and health products, providing comprehensive biotechnology solutions to customers [2]. - The main revenue composition of Yidoli includes: biological enzyme preparations (83.94%), plant extracts (8.34%), feed and feed additives (6.78%), and other products (0.95%) [2]. Financial Performance - As of September 30, Yidoli's total market capitalization is 3.344 billion yuan, with a recent stock price of 6.81 yuan per share [1]. - For the first half of 2025, Yidoli achieved operating revenue of 415 million yuan, a year-on-year increase of 4.48%, while the net profit attributable to shareholders decreased by 66.50% to 13.997 million yuan [2]. - Since its A-share listing, Yidoli has distributed a total of 359 million yuan in dividends, with 125 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, Yidoli has 20,100 shareholders, with an average of 24,399 circulating shares per person, showing no change from the previous period [2]. - Among the top ten circulating shareholders, the Guotai Zhongzheng Livestock Breeding ETF ranks as the sixth largest, holding 5.576 million shares, an increase of 850,600 shares compared to the previous period [3].

Core Points - The company announced that non-independent director Wu Chaoqun has resigned from all positions on the board due to adjustments in the corporate governance structure [1] - The company elected Zhuo Jiahui as the new employee representative director and appointed him to the audit committee and the remuneration and assessment committee to ensure the normal operation of the board [1] - Zhuo Jiahui's term will last from the date of election until the end of the eighth board's term [1]

股票代码：300381 股票简称：溢多利 公告编号：2025-047 广东溢多利生物科技股份有限公司 第八届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 广东溢多利生物科技股份有限公司（以下简称"公司"）第八届董事会第 十四次会议于 2025 年 10 月 16 日在公司会议中心以通讯方式召开。经全体董 事一致同意，本次会议豁免通知时限要求，会议通知于会议当天以电话与口头 方式送达全体董事。会议应出席董事 7 名，实际出席会议董事 7 名，部分高级 管理人员列席了本次会议。会议由董事长陈少美先生主持。本次会议符合《公 司法》和《公司章程》的有关规定，会议合法有效。 二、董事会会议审议情况 本次会议以投票表决方式审议通过了如下议案： 因公司治理结构调整，公司第八届董事会非独立董事伍超群先生于近日提 交辞职报告，辞去公司第八届董事会非独立董事、董事会审计委员会委员及董 事会薪酬与考核委员会委员职务，辞职后不再担任公司任何职务。伍超群先生 的辞职报告自送达公司之日起正式生效。 2025 年 10 月 15 日，公 ...

广东溢多利生物科技股份有限公司 关于董事辞职暨选举职工代表董事 及补选董事会部分专门委员会委员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、关于非独立董事辞职的情况 广东溢多利生物科技股份有限公司（以下简称"公司"）于近日收到公司 非独立董事伍超群先生提交的书面辞职报告，因公司治理结构调整，伍超群先 生辞去公司第八届董事会非独立董事、董事会审计委员会委员及董事会薪酬与 考核委员会委员职务，辞职后不再担任公司任何职务，其原定任期至第八届董 事会届满之日止。伍超群先生的辞职报告自送达公司之日起生效。 伍超群先生的辞职不会导致公司董事会成员低于法定最低人数，不会影响 公司董事会的正常运作。截至本公告披露日，伍超群先生未持有公司股票，不 存在应履行而未履行的承诺事项。辞去非独立董事职务后，将在原定任期内和 任期届满后六个月内继续遵守《上市公司董事和高级管理人员所持本公司股份 及其变动管理规则》《深圳证券交易所上市公司自律监管指引第 18 号——股东 及董事、高级管理人员减持股份》等法律法规的相关规定。 伍超群先生在任职期间恪尽职守、勤勉尽责，公司董事会对 ...